MyJournals Home  

RSS FeedsAbiraterone in `High-` and `Low-risk` Metastatic Hormone-sensitive Prostate Cancer (European Urology)

 
 

24 august 2019 03:00:18

 
Abiraterone in `High-` and `Low-risk` Metastatic Hormone-sensitive Prostate Cancer (European Urology)
 


A significant treatment benefit is observed in men with metastatic hormone-naïve prostate cancer treated with androgen deprivation therapy combined with abiraterone acetate and prednisolone, irrespective of being designated as having a `low` or a `high` risk by the current treatment criteria. This consistent result applies to all efficacy outcome measures.


 
233 viewsCategory: Urology
 
A Refined View on the Association Between Y-chromosome Microdeletions and Sperm Concentration (European Urology)
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts (European Urology)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten